

CORRECTION

Open Access



# Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease

Susanne Ostrowitzki<sup>1</sup>, Robert A. Lasser<sup>2</sup>, Ernest Dorflinger<sup>3</sup>, Philip Scheltens<sup>4</sup>, Frederik Barkhof<sup>4,5,6</sup>, Tania Nikolcheva<sup>6</sup>, Elizabeth Ashford<sup>7</sup>, Sylvie Retout<sup>8</sup>, Carsten Hofmann<sup>8</sup>, Paul Delmar<sup>9</sup>, Gregory Klein<sup>6</sup>, Mirjana Andjelkovic<sup>8</sup>, Bruno Dubois<sup>10</sup>, Mercè Boada<sup>11</sup>, Kaj Blennow<sup>11</sup>, Luca Santarelli<sup>12</sup>, Paulo Fontoura<sup>9\*</sup> and for the SCarlet RoAD Investigators

## Correction

Following publication of the original article [1], the authors reported errors in the formatting of the table. The details of the errors are as follows:

In Table 1, the data presented do not correspond to the row title:

- The education row currently contains incorrect data.
- The weight row currently contains the years of education.
- The APOEε4 genotype row currently contains the weight data.

In Table 1, the data should be displayed as follows:

Variable	
Intention-to-treat population ( <i>n</i> = 797)	
Placebo	
( <i>n</i> = 266)	
Gantenerumab	
105 mg	
( <i>n</i> = 271)	
Gantenerumab	
225 mg	
( <i>n</i> = 260)	
Age, years, mean (SD)	
69.5 (7.5)	
70.3 (7.0)	
71.3 (7.1)	
Education, years, mean (SD)	
12.6 (4.3)	

12.9 (4.8)	
12.1 (4.5)	
Weight, kg, mean (SD)	
69.8 (12.9)	
70.5 (13.6)	
70.1 (12.5)	
APOEε4 genotype, % <sup>a</sup>	

## Author details

<sup>1</sup>Product Development, Neuroscience, Genentech Inc., South San Francisco, CA, USA. <sup>2</sup>MedDay Pharmaceuticals, Boston, MA, USA. <sup>3</sup>Formerly Roche Translational & Clinical Research Center, New York, NY, USA. <sup>4</sup>VU University Medical Center, Amsterdam, The Netherlands. <sup>5</sup>Institute of Neurology, UCL, London, UK. <sup>6</sup>Roche Pharma Research and Early Development, NORD, Basel, Switzerland. <sup>7</sup>Roche Products Limited, Welwyn Garden City, UK. <sup>8</sup>Roche Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center, Basel, Switzerland. <sup>9</sup>Clinical Pharmacology and Bioanalytical R&D, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. <sup>10</sup>Alzheimer Institute and ICM, UMR-S975, Salpêtrière University Hospital, AP-HP, Pierre and Marie Curie University, Paris, France. <sup>11</sup>Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain. <sup>12</sup>Formerly Roche Pharma Research and Early Development, NORD, Basel, Switzerland.

Published online: 27 September 2018

## Reference

1. Ostrowitzki S, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. *Alzheimer's Research & Therapy*. 2017;9:95. <https://doi.org/10.1186/s13195-017-0318-y>.

\* Correspondence: [paulo.fontoura@roche.com](mailto:paulo.fontoura@roche.com)

<sup>9</sup>Clinical Pharmacology and Bioanalytical R&D, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

